pared. These changes are summarized in figure 1 . The introduction of genotypes that were formerly unknown in this risk population (4 and 2a/b) and the ability of these genotypes to establish significant prevalence within a period of only 6 years are remarkable.
The theory of 2 independently developing HCV epidemics had been proposed elsewhere [4] , because the epidemiology of HCV subtype 3a and other subtypes seemed to be very different between IDUs and non-IDUs. However, there are indications that the dynamics observed among IDUs also influence the genotypic distribution among the entire population of patients. Although subtype 3a was detected nearly exclusively among IDUs in 1994-1995, ∼45% of patients infected with subtype 3a had never been IDUs. In the majority of these people, high-risk sexual behavior (HRSB) was the most probable risk factor for acquiring HCV infection [3] . It can be assumed from these data that the higher the prevalence of a certain genotype among the population of IDUs, the higher is the risk of this genotype spreading beyond the boundaries of the IDU scene. This is most probably due to HRSB, which, today, is one of the major risk factors for acquiring HCV [3, 5] . On the other hand, new genotypes can be introduced in the population of IDUs. This has been demonstrated very convincingly for genotype 4, which was introduced by immigrants from northern Africa and the Arabian peninsula [1, 3] , and for genotype 2 [3] . In our population of patients, these genotypes established a prevalence of 7% and 8%, respectively, within only 6 years ( figure 1) . In analogy to the findings for subtype 3a, these genotypes may also spread over the boundaries of the IDU scene with increasing prevalence.
However, knowledge of these dynamic changes of the distribution of HCV genotypes provides information regarding not only the epidemiology, but also the treatment, of HCV. In a population with a high risk of repeated HCV infections, the probability of infection with different HCV genotypes is associated with the speed of changes of the genotype distribution. We have shown that, in at least 18% of IDUs with long-term follow-up (up to 7 years), multiple HCV infections detected by intraindividual changes of the predominant HCV genotype occurred [6] .
It is well known that, in patients infected with multiple HCV genotypes, one of the infecting virus strains establishes predominance, and, by use of polymerase chain reaction-based methods, usually only the actual prevailing strain can be detected in these patients [7] . However, minor strains do not become eliminated, and we have demonstrated in various patients that these minor strains can reappear [6, 8] . These findings are of importance, especially in the context of therapy with pegylated interferon and ribavirin. It has been shown that reemergence of minor strains is a possible cause for failure of therapy [6, 8] . Therefore, the recommendation was made to repeat genotyping in patients who do not respond to therapy as expected. This enables adjustment of the regimen to the actual predominant HCV genotype.
These findings underline the importance of the described dynamic changes of the epidemiological distribution of HCV genotypes among IDUs They are important for better understanding (1) the epidemiology of HCV and (2) possible factors influencing outcome of therapy.
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